Ok, this this may mean we have to postpone the party with Kamoa but the perverse market may now start to value the entire vphm story rather than punish all products for the generic overhang. Its gone now, no point crying, but from here there are no more clouds overhaning analysts evaluations.
It may take a few days for the dust to settle but from here we are building on as solid a foundation as a company in the pharma business can hope for.
Best regards to all, especially the old-timers who will have flash backs to when the generic bomb initially landed on us. No surf for us this month))